Literature DB >> 22808954

Two centuries of assessing drug risks.

Jerry Avorn1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22808954     DOI: 10.1056/NEJMp1206652

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  The out-of-focus bias in drug surveillance.

Authors:  Markus Gnädinger; Hans-Ulrich Mellinghoff
Journal:  Eur J Clin Pharmacol       Date:  2012-08-16       Impact factor: 2.953

2.  Has evidence-based medicine left quackery behind?

Authors:  Florian Naudet; Bruno Falissard; Rémy Boussageon; David Healy
Journal:  Intern Emerg Med       Date:  2015-04-01       Impact factor: 3.397

3.  Making individualized drugs a reality.

Authors:  Huub Schellekens; Mohammed Aldosari; Herre Talsma; Enrico Mastrobattista
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

4.  The Potential Return on Public Investment in Detecting Adverse Drug Effects.

Authors:  Krista F Huybrechts; Rishi J Desai; Moa Park; Joshua J Gagne; Mehdi Najafzadeh; Jerry Avorn
Journal:  Med Care       Date:  2017-06       Impact factor: 2.983

5.  Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population.

Authors:  Robert Eriksson; Thomas Werge; Lars Juhl Jensen; Søren Brunak
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

6.  The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.

Authors:  Florian Erhel; Alexandre Scanff; Florian Naudet
Journal:  Epidemiol Psychiatr Sci       Date:  2020-04-27       Impact factor: 6.892

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.